Neuropathic Pain

1. What is Neuropathic Pain?
2. Peripheral vs. Central Sensitization
3. Common Causes and Conditions
4. How Neuropathic Pain Feels: Symptoms and Descriptors
5. DN4 Diagnostic Tool
6. Diagnosing the Underlying Cause
7. Gabapentinoids: Mechanism and Efficacy
8. SNRI Treatment: Duloxetine
9. Topical Treatments
10. Alpha-Lipoic Acid and Evidence
11. Other Treatment Options
12. Complications
13. Key Research Papers
14. Connections

What is Neuropathic Pain?

Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system — the network of nerves responsible for sensing and transmitting information about pain, temperature, touch, and position. Unlike nociceptive pain (the normal protective pain signal from injured tissue — a stubbed toe, a burn), neuropathic pain arises from abnormal firing of damaged nerves themselves. The pain persists even when no tissue damage is occurring, and standard pain relievers often provide little relief. It affects an estimated 7–10% of the general population. Quality of life impacts are profound: sleep disruption, depression, anxiety, and reduced ability to work and socialize are common.

Back to Table of Contents

Peripheral vs. Central Sensitization

Understanding the difference helps explain why neuropathic pain is so hard to treat:

• Peripheral sensitization: Damaged peripheral nerves (outside the brain and spinal cord) develop ectopic firing — they spontaneously generate pain signals without a stimulus. Damaged nerves may also sprout abnormally, acquire new sodium channels, and become hypersensitive to normally harmless stimuli (such as light touch causing pain — allodynia).
• Central sensitization: Prolonged or intense peripheral nociceptive input changes the spinal cord and brain. NMDA receptors in the dorsal horn become hyperexcitable ("wind-up"); inhibitory pathways (serotonin-norepinephrine descending pain modulation) become less effective; the brain's pain matrix is reorganized to amplify signals. Central sensitization means that even after peripheral nerve healing, the central nervous system continues generating pain. It also explains why treatments that work on peripheral nerves alone often fail in long-standing neuropathic pain.

Back to Table of Contents

Common Causes and Conditions

• Diabetic peripheral neuropathy: Most common cause in the US; ~50% of long-term diabetics develop it; stocking-glove distribution (feet/hands)
• Postherpetic neuralgia (PHN): Persistent pain after herpes zoster (shingles); risk increases sharply with age
• Trigeminal neuralgia: Severe brief electric-shock pain in the face; most common cause is blood vessel compression of the trigeminal nerve
• Chemotherapy-induced peripheral neuropathy (CIPN): Taxanes, platinum compounds, vinca alkaloids, bortezomib
• HIV-associated neuropathy: Direct viral infection of neurons and immune-mediated damage
• Small fiber neuropathy (SFN): Affects unmyelinated C fibers and lightly myelinated Aδ fibers; often overlooked; skin biopsy for diagnosis
• Complex Regional Pain Syndrome (CRPS): Overlaps substantially with neuropathic pain
• Spinal cord injury: Central neuropathic pain above and below the injury level
• Phantom limb pain: Pain perceived in an amputated limb; related to cortical remapping
• Post-surgical neuropathic pain: Thoracotomy, mastectomy, hernia repair (inguinal nerve injury)
• Radiculopathy: Nerve root compression from disc herniation (sciatica is the most common example)
• Multiple sclerosis: Central neuropathic pain from demyelinating lesions
• Idiopathic small fiber neuropathy: No identifiable cause; possibly immune-mediated in many cases

Back to Table of Contents

How Neuropathic Pain Feels: Symptoms and Descriptors

Neuropathic pain has a distinctive character that distinguishes it from musculoskeletal pain. Patients describe:

• Burning: The most characteristic description — a continuous burning or heat sensation, often in the skin surface
• Electric shocks: Brief, lancinating shooting pain like an electric jolt
• Tingling and pins-and-needles (paresthesia): Usually present even at rest
• Numbness: Paradoxically, areas can be both numb AND painful simultaneously
• Allodynia: Pain from stimuli that should not hurt — light touch of clothing, a breeze, water from the shower
• Hyperalgesia: Exaggerated pain response to stimuli that are mildly painful
• Wind-up: Repeated stimulation causes escalating pain (due to central sensitization)
• Spontaneous pain at rest: Pain is present without any stimulus at all
• Worse at night: Very commonly disturbs sleep

Back to Table of Contents

DN4 Diagnostic Tool

The Douleur Neuropathique 4 (DN4) questionnaire is the most widely validated bedside tool for identifying neuropathic pain. It has a sensitivity of 82.9% and specificity of 89.9% for neuropathic pain vs. nociceptive pain. Score ≥4/10 indicates neuropathic pain.

Interview questions (patient reports):

1. Does the pain have a burning quality?
2. Is there a sensation of painful cold?
3. Does the pain resemble electric shocks?
4. Does pain feel like tingling?
5. Does it feel like pins and needles?
6. Does it feel like numbness?

Examination findings (clinician tests):

7. Is the pain area hypoesthetic to touch?
8. Is the pain area hypoesthetic to pinprick?
9. Does brushing increase pain in the area?
10. Does the pain area have autonomic signs?

Back to Table of Contents

Diagnosing the Underlying Cause

Diagnostic workup depends on clinical features and distribution. Standard evaluation includes:

• Detailed neurological examination
• Fasting glucose, HbA1c (diabetes)
• B12 and folate (deficiency neuropathy)
• TSH (hypothyroid neuropathy)
• CBC and ESR/CRP
• Serum protein electrophoresis (SPEP) for paraproteinemia
• Nerve conduction studies (NCS) and electromyography (EMG) — evaluate large fiber function
• Skin punch biopsy for intraepidermal nerve fiber density — the gold standard for small fiber neuropathy diagnosis
• MRI for radiculopathy or central causes
• Genetic testing if hereditary neuropathy suspected (Charcot-Marie-Tooth)

Back to Table of Contents

Gabapentinoids: Mechanism and Efficacy

Gabapentin (Neurontin) and pregabalin (Lyrica) are first-line agents for many neuropathic pain types. Despite the name, they do not work at GABA receptors. Their actual mechanism: they bind to the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels on presynaptic nerve terminals in the dorsal horn of the spinal cord. This reduces calcium influx and therefore decreases neurotransmitter release (including substance P, glutamate, and CGRP) — dampening central sensitization.

Efficacy: NNT (number needed to treat for 50% pain relief) is approximately 4–8 for diabetic neuropathy and postherpetic neuralgia — meaning 4–8 patients must be treated for one to benefit. Response is variable and cannot be predicted.

Dosing: Gabapentin starts at 100–300 mg at bedtime, increases slowly to 900–3600 mg/day in divided doses. Pregabalin (faster onset, more linear absorption) starts at 75 mg twice daily, increases to 150–300 mg twice daily.

Side effects: sedation, dizziness, weight gain, peripheral edema, cognitive dulling — often dose-limiting. New pharmacovigilance concerns about misuse/dependence (particularly gabapentin) in the UK and some US states.

Back to Table of Contents

SNRI Treatment: Duloxetine

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a first-line option for diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain.

Mechanism: Inhibit reuptake of both serotonin and norepinephrine in the descending pain modulation pathways from the periaqueductal gray and brainstem to the dorsal horn — enhancing the body's own pain-suppression circuitry. Norepinephrine is the key mediator (explains why NRI>SSRI for pain).

Duloxetine (Cymbalta): FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Dose: 30 mg daily for 1 week then 60 mg daily. NNT ~5 for 50% pain relief in diabetic neuropathy. Common side effects: nausea (usually transient), dry mouth, insomnia, sexual dysfunction, modest BP increase.

Venlafaxine: Alternative SNRI; evidence in painful polyneuropathy; higher NE effect at higher doses (≥150 mg/day); requires cardiac monitoring at higher doses.

Back to Table of Contents

Topical Treatments

Topical agents allow higher local drug concentrations at the site of pain with minimal systemic absorption and side effects:

• Lidocaine 5% patch (Lidoderm): FDA-approved for postherpetic neuralgia; applied to the most painful skin area for up to 12 hours/day; blocks sodium channels in peripheral nerve terminals; essentially no systemic effect; can be cut to fit; particularly useful in allodynia
• Capsaicin 8% patch (Qutenza): Applied in clinic under local anesthesia for 60 minutes; causes initial intense burning then prolonged desensitization of TRPV1-expressing C fibers; duration of relief 3–6 months; requires re-application
• Capsaicin 0.025–0.1% cream (OTC): Applied 3–4 times daily; requires 4–6 weeks for effect; compliance limited by initial burning
• Amitriptyline 2–5% cream: Compounded; used off-label for local neuropathic pain (postherpetic neuralgia, localized polyneuropathy); systemic TCA avoided
• Topical NSAIDs (diclofenac gel): More useful for musculoskeletal than pure neuropathic pain but can help in mixed presentations

Back to Table of Contents

Alpha-Lipoic Acid and Evidence

Alpha-lipoic acid (ALA) is a naturally occurring antioxidant made by the body and found in small amounts in spinach, broccoli, and red meat. It plays a role in mitochondrial energy metabolism. For neuropathic pain, it acts as:

• Potent antioxidant: Scavenges reactive oxygen species that damage peripheral nerve fibers; regenerates vitamins C and E; improves endoneurial blood flow in diabetic neuropathy
• Mitochondrial support: Restores nerve energy metabolism impaired by diabetes and other causes

Clinical evidence: ALA is the most evidence-supported natural treatment for diabetic peripheral neuropathy. The landmark SYDNEY trials (intravenous ALA 600 mg/day × 3 weeks) showed significant reduction in total symptom score vs. placebo. Oral ALA at 600 mg three times daily (1800 mg/day) is effective in multiple trials, though effect size is modest. The SYDNEY 2 trial (oral) showed NNT of ~6. ALA is approved as a drug for diabetic neuropathy in Germany. In the US it is sold as a supplement (R-lipoic acid — the more bioavailable form — or racemic R+S).

Dose: 600 mg three times daily; less effective once daily at the same total dose. Side effects: GI upset, rash; not for use in thiamine-deficient patients (can worsen thiamine deficiency).

Back to Table of Contents

Other Treatment Options

• Tricyclic antidepressants (TCAs): Amitriptyline, nortriptyline — oldest medications proven for neuropathic pain; work via norepinephrine/sodium channel mechanism; very cheap; limited by anticholinergic side effects (dry mouth, constipation, urinary retention, sedation) and cardiac risk in overdose/elderly; use nortriptyline (fewer side effects) when TCA is preferred
• Opioids: Tramadol has combined opioid + SNRI mechanism; modest NNT for neuropathic pain; other opioids are third-line due to tolerance, dependence, and modest long-term evidence
• Low-dose naltrexone (LDN): 1.5–4.5 mg at bedtime; anti-inflammatory via microglial TLR4 blockade; evidence in fibromyalgia and small fiber neuropathy
• Sodium channel blockers: Carbamazepine/oxcarbazepine — first-line for trigeminal neuralgia specifically; blocks ectopic nerve firing
• Spinal cord stimulation (SCS): FDA-approved for failed back surgery syndrome and CRPS; strong evidence; reversible
• Transcranial magnetic stimulation (TMS): Emerging evidence for central neuropathic pain
• Ketamine: IV infusions in specialized centers for refractory central and peripheral neuropathic pain

Back to Table of Contents

Complications

Neuropathic pain complications cascade: sleep deprivation from nocturnal pain leads to daytime fatigue and cognitive dysfunction; depression (40–65% prevalence in neuropathic pain); anxiety and catastrophizing (amplify pain perception); reduced physical activity leads to deconditioning and worsening pain; disability and unemployment; medication side effects (especially sedation with gabapentinoids and anticholinergic effects with TCAs); in diabetic neuropathy — loss of protective sensation leads to foot ulcers, infections, and amputations (entirely preventable with proper foot care and glucose control).

Back to Table of Contents

Key Research Papers

1. Treede RD et al., 2008 — PMID: 18003941 — Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology.
2. Bouhassira D et al., 2004 — PMID: 14987272 — Development and validation of the Neuropathic Pain Symptom Inventory. Pain.
3. Bouhassira D et al., 2005 — PMID: 15694698 — Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain.
4. Finnerup NB et al., 2015 — PMID: 25575710 — Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol.
5. Raskin J et al., 2005 — PMID: 16083475 — A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med.
6. Ziegler D et al., 1995 — PMID: 7589875 — Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. Diabetologia.
7. Ziegler D et al., 2006 — PMID: 16936160 — Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care.
8. Derry S et al., 2014 — PMID: 25058164 — Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev.
9. Cruccu G et al., 2016 — PMID: 27511815 — EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol.
10. Moore RA et al., 2011 — PMID: 21412914 — Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev.
11. Wiffen PJ et al., 2016 — PMID: 27572926 — Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev.

PubMed Topic Searches

• neuropathic pain gabapentin pregabalin
• duloxetine neuropathic pain diabetic
• alpha lipoic acid diabetic neuropathy
• topical lidocaine postherpetic neuralgia
• small fiber neuropathy skin biopsy
• central sensitization chronic pain

Back to Table of Contents

Connections

• Chronic Pain
• Complex Regional Pain Syndrome
• Migraine
• Fibromyalgia
• Trigeminal Neuralgia
• Type 2 Diabetes
• Vitamin B12
• Magnesium

Back to Table of Contents

Featured Videos